US Activist Hedge Fund Institutional SEC 13D 13G — September 15, 2026

15-09-2026

T3 Defense Inc., Water IO Ltd., and related parties filed a final amendment to their Schedule 13D, exiting their position as beneficial owners of more than 5% of Tessera Defense & Homeland Security Inc. (formerly BiomX Inc.). On September 15, 2026, Water IO acquired 26,796 shares of common stock, bringing its total holdings to 156,796 shares, representing approximately 3.87% of the outstanding shares. The amendment also confirms payment of $500,000 in principal installments and extends the deadline for issuing the remaining 53,205 shares to November 30, 2026, subject to stockholder approval.

• · The Reporting Persons ceased to be beneficial owners of more than 5% of the Issuer's common stock as of September 15, 2026.
• · The 26,796 shares issued on September 15, 2026 are not registered for resale.
• · The remaining 53,205 shares owed to Water IO may be satisfied by a transfer of an equivalent number of shares by a third party, or by a cash payment if not issued by June 30, 2027.
• · The NYSE American authorized the listing of only 26,796 shares without stockholder approval under Section 713 of the NYSE American Company Guide.
• · The Issuer has instructed its transfer agent to issue 26,796 shares to Water IO in restricted book-entry form.

15-09-2026

Milton C. Ault III and his affiliated entity Ault & Company, Inc. filed a Schedule 13D/A disclosure revealing a combined beneficial ownership of 63.5% (318,613,936 Class A Shares) of Hyperscale Data, Inc.'s total Class A Common Stock, with Ault & Company holding 317,568,715 shares (63.3%). However, when factoring in the separate voting power of Class B shares (10 votes each) and NYSE restrictions on preferred stock conversion, their overall voting power drops to 14.45% for Mr. Ault and 14.12% for Ault & Company, representing a significant decline from the nominal ownership percentage. Other individual insiders—William B. Horne, Henry Carl Nisser, and Kenneth S. Cragun—collectively own roughly 550,000, 437,500, and 225,000 shares respectively, each less than 1% of total shares. No period-over-period comparisons are available in this filing (all data is point-in-time as of September 14, 2026).

• · The conversion price for Series C, G, and H Preferred Stock is the greater of $0.10 per share and 105% of the VWAP over the prior 10 trading days; the filing uses $0.1763 for calculation.
• · Ault & Company holds 127,813 Class A Shares from outstanding warrants, including 84,470 from the Series C deal, 32,444 from the Series G deal, and 10,899 from the repaid senior secured convertible promissory note.
• · Stock options awarded to Messrs. Ault, Horne, Nisser, and Cragun are for the purchase of 400,000, 400,000, 300,000, and 200,000 Class A Shares respectively, with a strike price of $3.60, expiring July 30, 2035. 50% vested on May 6, 2026 (date of stockholder and NYSE American approval), the remaining 50% vest monthly over 24 months starting June 1, 2026.
• · The filing reports Amendment No. 19 to the original Schedule 13D filed October 12, 2021; no material portfolio changes from the previous amendment were specified.
• · Details of purchase prices are historical (not compared to prior periods); no period-over-period comparisons exist in this filing.

15-09-2026

Tricor Pacific Capital Inc. and its wholly-owned subsidiary Tricor PMT25 Holdings Inc. filed an amended Schedule 13D disclosing that, as of September 14, 2026, they beneficially own 2,701,056 shares of CPI Card Group Inc. common stock, representing 23.45% of the outstanding shares. The filing reports that on September 14, 2026, the subsidiary purchased an additional 525,000 shares at $21.50 per share for a total of $11,287,500 in a registered secondary offering. The increase in ownership does not reflect any change in Tricor's previously stated investment purposes.

• · The additional 525,000 shares were purchased at $21.50 per share, funded by Tricor's working capital.
• · On December 4, 2025, Sub purchased 1,926,056 restricted shares in a privately negotiated transaction and entered into a Director Nomination Agreement granting pro rata board nomination rights (up to two directors).
• · Sub also became party to a Registration Rights Agreement dated October 15, 2015, and agreed to a one-year lock-up on the restricted shares.
• · Prior to the December 2025 purchase, Tricor already held 250,000 shares purchased in September 2024.
• · The Reporting Persons disclaim any present plan or proposal for actions under Item 4 of Schedule 13D beyond those described.

15-09-2026

Al Shams Investments Limited (ASIL), a Bermuda-based private investment company, filed an amended Schedule 13D disclosing a 9.48% beneficial ownership stake in Braemar Hotels & Resorts Inc. (BHR) as of September 13, 2026. On that date, ASIL delivered a nomination notice to BHR nominating five director candidates, including Jennifer L. Bitterman and Anna Massion, for election at the 2026 Annual Meeting scheduled for November 13, 2026. The filing highlights the nominees' extensive real estate and finance experience, including Bitterman's role in a $1 billion portfolio refinancing and Klein's $10 billion transaction experience, but notes no recent securities law violations by the reporting persons.

• · ASIL's principal business address is 5B Waterloo Lane, Pembroke HM 08, Bermuda.
• · The Nomination Notice was hand delivered to the Issuer on September 14, 2026.
• · Jennifer L. Bitterman served as Global CFO of GSA Group since June 2025 and previously as CFO of Cedar Realty Trust from September 2021 to August 2022.
• · Anna Massion served as a Non-Executive Director at Playtech PLC from April 2019 to February 2025 and at Artemis Strategic Investment Corporation from October 2021 to October 2023.
• · Sir Michael Peat served as Keeper of the Privy Purse and Treasurer to The Queen from 1996 to 2002.
• · None of the Reporting Persons has been subject to a judgment or decree for securities law violations in the last five years.

15-09-2026

Stone House Capital Management, LLC and affiliates filed Amendment No. 1 to their Schedule 13D, disclosing a 16.1% beneficial ownership stake in Designer Brands Inc. (DBI), representing 7,000,000 Class A Common Shares. The filing highlights management's disclosure that Topo Athletic is on track to exceed $100 million in revenue in 2027, which the Reporting Persons believe could become DBI's largest value driver. The group continues to view the shares as significantly undervalued and seeks constructive dialogue with management and the Board.

• · The Schedule 13D was initially filed on June 11, 2026, and this Amendment No. 1 was filed on September 15, 2026.
• · The Reporting Persons include Stone House Capital Management, LLC, SH Capital Partners, L.P., and Mark A. Cohen.
• · The beneficial ownership is based on 43,390,683 shares outstanding as of September 3, 2026, as reported in the Issuer's Form 10-Q filed on September 10, 2026.
• · The filing includes a presentation (Exhibit 99.1) summarizing the Reporting Persons' views on Topo Athletic's potential to create significant long-term value.
• · The Reporting Persons believe Topo Athletic has substantial runway for growth and increasing awareness within the running community.

15-09-2026

Kaspi.kz increased its stake in D-MARKET Electronic Services & Trading (HEPS) to 93.51% by acquiring 19,547,401 ADSs from VR Global Partners for $57.7 million ($2.95/ADS). This acquisition further consolidates Kaspi.kz's controlling position in the Turkish e-commerce company, which already held a substantial majority stake prior to this transaction.

• · The acquisition was funded from Kaspi.kz's working capital.
• · The purchase was made pursuant to a VR Purchase Agreement entered into on September 10, 2026.
• · Kaspi.kz has sole voting and dispositive power over all 400,841,947 Ordinary Shares.
• · This is Amendment No. 10 to the original Schedule 13D filed on February 5, 2025.
• · The Issuer's ADSs are listed on the Nasdaq Global Select Market under the symbol 'HEPS'.

15-09-2026

Alternative Liquidity Index LP and related entities filed a Schedule 13D disclosing beneficial ownership of 225,010,000 shares of General Steel Holdings Inc common stock, representing 83.0% of the 271,013,956 shares outstanding as of September 11, 2026. The stake was acquired through the conversion of 100 shares of Series C Preferred Stock into 225,000,000 common shares on September 11, 2026, plus 10,000 shares held prior to conversion. The reporting persons include Alternative Liquidity Index LP, its general partner Alternative Liquidity GP LLC, its investment manager Alternative Liquidity Capital Management LLC, and Jacob Nicholas Mohs, who is the sole managing member of the management company.

• · The Stock Issuance Agreement was entered into on December 29, 2023, under which 100 shares of Series C Preferred Stock were issued to LP as consideration for services to rehabilitate the company.
• · On August 19, 2026, the board resolved to amend the Articles of Incorporation to authorize 500,000,000 common shares and 5,000,000 preferred shares.
• · None of the reporting persons have been convicted in a criminal proceeding or been party to a securities-related civil proceeding in the last five years.
• · The reporting persons are organized under Delaware law (LP, GP, Management) and Mr. Mohs is a U.S. citizen.

15-09-2026

Thomas John Corley filed a Schedule 13G/A with the SEC on September 15, 2026, disclosing beneficial ownership of 714,000 shares of SOBR Safe, Inc. common stock, representing 13.3% of the outstanding shares. The filing indicates no change in Corley's holdings from the prior filing, and the shares are not held with the purpose of changing or influencing control of the company.

• · The filing is an amendment (Schedule 13G/A) to a prior Schedule 13G.
• · Corley's ownership is passive, as certified under Rule 13d-1(c).
• · The company's common stock has a par value of $0.00001 per share.
• · The company's former names include TransBiotec, Inc. and IMAGINE MEDIA LTD.

15-09-2026

NutriBand Inc. CEO Gareth Sheridan filed a Schedule 13D/A disclosing beneficial ownership of 1,786,000 common shares, representing 14.2% of the company's outstanding stock as of September 14, 2026. The stake includes 1,510,000 founder shares issued in 2016 and options to purchase 276,000 shares at exercise prices from $2.12 to $8.07, none of which have been exercised. The filing indicates the CEO may buy or sell shares depending on market conditions and may engage in discussions with the board regarding strategic alternatives.

• · Options granted to CEO have exercise prices ranging from $2.12 to $8.07, issued between January 21, 2021 and July 15, 2026.
• · None of the options granted under the stock option plan have been exercised as of the filing date.
• · The CEO may engage in discussions with the board regarding potential business combinations, strategic alternatives, capital structure, governance, and management.
• · The CEO may acquire additional shares, sell shares, or distribute shares to other entities depending on market conditions and other factors.

15-09-2026

A.L. Sarroff Fund, LLC, together with Alan Sarroff and Eileen Sarroff, disclosed a 38.2% beneficial ownership stake in PetVivo Holdings, Inc. as of September 14, 2026, representing 16,940,839 common shares based on 37,950,495 shares outstanding. During the past 60 days, the Reporting Persons made several open-market purchases: Mrs. Sarroff acquired 580 shares at $0.687 on Aug 27 and 22,160 shares at $0.679 on Sep 9; Mr. Sarroff bought 10,974 shares at $0.677 on Sep 10 and 24,888 shares at $0.689 on Sep 14, signaling continued accumulation. The filing also notes the potential exercise of warrants for an additional 6,442,508 shares, which would further increase their ownership percentage.

• · Total outstanding common shares as of August 14, 2026: 37,950,495
• · Warrants to purchase 6,442,508 shares of common stock are outstanding and assumed exercisable
• · Reporting Persons may enter into swaps, options or other derivative transactions based on common stock value

15-09-2026

Selwyn Isakow and Hilary Isakow filed a Schedule 13G with the SEC, disclosing collective beneficial ownership of 592,397 shares of Private Bancorp of America, Inc. (PBAM) common stock, representing 10.3% of the 5,729,788 shares outstanding as of August 31, 2026. Selwyn Isakow individually beneficially owns 390,599 shares (10.3%), while Hilary Isakow beneficially owns 201,798 shares (3.5%). The filing is a routine disclosure of passive ownership under Rule 13d-1(d) and does not indicate any change in control or active engagement.

• · The filing is made under Rule 13d-1(d) (passive investor exemption).
• · Selwyn Isakow's beneficial ownership includes shares held directly, through family trusts, his retirement account, and Hilsel Investment Company L.P.
• · Hilary Isakow's beneficial ownership consists solely of shares held by family trusts for which she serves as sole trustee.
• · The percentage calculations are based on 5,729,788 shares outstanding as of August 31, 2026, per the Issuer's Form 10-Q filed September 4, 2026.

15-09-2026

Braeden Lichti and Northstrive Fund II LP have sold all of their shares in enVVeno Medical Corp, exiting their positions entirely. Lichti sold his shares on September 11, 2026, and Northstrive Fund sold its shares between September 11 and September 14, 2026. This Schedule 13D/A is the final amendment and constitutes an exit filing for both reporting persons, who now own zero shares of the company's common stock.

• · Braeden Lichti sold all his shares on September 11, 2026.
• · Northstrive Fund II LP sold all its shares between September 11 and September 14, 2026.
• · Both reporting persons now own 0 shares of enVVeno Medical Corp common stock.
• · This filing is the final amendment to the Schedule 13D and constitutes an exit filing.
• · Lichti is a Canadian citizen; Northstrive Fund is a Delaware limited partnership.
• · Lichti previously used personal funds to purchase his shares; Northstrive Fund used working capital.

15-09-2026

D. E. Shaw & Co., L.P. and David E. Shaw disclosed beneficial ownership of 28,765,945 shares of Venture Global, Inc. Class A common stock, representing a 5.4% stake, as of September 11, 2026. D. E. Shaw & Co., L.L.C. separately reported ownership of 26,604,375 shares, or 5.0% of the outstanding shares. The filing indicates a passive investment intent, with no purpose or effect of changing or influencing control of the issuer.

• · The filing was made pursuant to Rule 13d-1(c), indicating a passive investment.
• · David E. Shaw does not own any shares directly; his beneficial ownership is attributed through his control of D. E. Shaw entities.
• · D. E. Shaw & Co., L.P. has shared power to vote or direct the vote of 28,573,445 shares and shared power to dispose of 28,765,945 shares.
• · D. E. Shaw & Co., L.L.C. has shared power to vote or direct the vote of 26,604,375 shares and shared power to dispose of 26,604,375 shares.
• · The filing includes a Joint Filing Agreement dated September 15, 2026.

15-09-2026

GL Part SPV II, LLC filed a Schedule 13D disclosing beneficial ownership of 27,479,983 shares of XCF Global, Inc. Class A Common Stock, representing a 6.7% stake. The position was built through two transactions: 20,588,185 shares acquired on June 6, 2025 via a business combination agreement, and an additional 6,891,798 shares acquired on September 14, 2026 through a Common Stock Purchase Warrant. GL II also has the right to acquire warrants to purchase up to $99,000,000 of additional shares until December 31, 2026, at an exercise price of $2.50 per share.

• · GL II's primary business is investing in XCF and other companies involved in the sustainable aviation fuel business.
• · GL II has not been a party to any proceeding required to be disclosed pursuant to Item 2(e).
• · The warrants are exercisable on a paid or cashless basis at $2.50 per share.
• · The Reporting Persons may purchase and sell common stock of XCF in their sole discretion, subject to applicable law.
• · The amount of warrants to be acquired and the price applicable thereto is unknown at this time for the additional warrants.

15-09-2026

Razor's Edge Fund III, LP and affiliated entities disclosed beneficial ownership of 12,727,273 shares of AEVEX Corp. Class A common stock, representing 18.4% of the outstanding shares as of September 8, 2026. The shares are directly held by Black Sea Technologies LLC, with Razor's Edge entities sharing voting and investment authority. The filing is a routine Schedule 13G under Rule 13d-1(c), indicating passive investment intent.

• · The filing is made pursuant to Rule 13d-1(c), indicating passive investment intent.
• · All Reporting Persons are organized in Delaware.
• · The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G.
• · The percentage calculation is based on 56,470,333 shares outstanding on August 12, 2026, plus 12,727,273 shares issued to Black Sea on September 8, 2026.

15-09-2026

Nistec Golan Ltd., controlled by CEO and Chairman Yitzhak Nissan, filed a Schedule 13D/A disclosing a 60.23% beneficial ownership stake in Eltek Ltd. as of September 14, 2026. Mr. Nissan directly owns an additional 2.46% of shares, bringing his combined beneficial ownership to 62.68%. The filing details a series of open-market share purchases by Nistec Golan between July and September 2026, including a large block of 169,357 shares acquired on September 14, 2026 at $9.00 per share for $1.52M.

• · Nistec Golan acquired shares in 34 separate open-market transactions between July 14, 2026 and September 15, 2026, with share prices ranging from $7.97 to $9.41.
• · The largest single acquisition was 169,357 shares on September 14, 2026 at $9.00 per share for a total of $1,524,213.
• · The filing is an amendment to a previous Schedule 13D, indicating ongoing accumulation of shares by the reporting persons.
• · Yitzhak Nissan controls Nistec Golan Ltd. and serves as Chairman of the Board of Eltek Ltd.

15-09-2026

Magnolia Capital Fund, LP and related entities (collectively the 'Reporting Persons') filed an amended Schedule 13D on September 15, 2026, disclosing a 22.6% beneficial ownership stake in Boston Omaha Corp (BOC). The filing was triggered by a BOC share repurchase program announced on September 11, 2026, which reduced the total Class A shares outstanding from 29,546,008 to an estimated 29,298,236, thereby increasing the Reporting Persons' ownership percentage. Adam K. Peterson, managing member of The Magnolia Group, LLC, is deemed the beneficial owner of 6,756,842 shares, representing 22.6% of the combined Class A and Class B shares outstanding.

• · The Reporting Persons have not acquired or disposed of any shares in the past 60 days; the filing reflects a change in ownership percentage due solely to the issuer's share buyback.
• · Class B common stock (580,558 shares) is convertible into Class A common stock on a one-for-one basis at any time with no expiration.
• · Adam K. Peterson indirectly purchased 876 shares for his minor children's accounts at a cost basis of $15,017.33 on September 11, 2023.
• · The Reporting Persons state the purpose of the investment is for investment purposes and that shares were acquired based on the belief they were undervalued.

15-09-2026

Venrock Healthcare Capital Partners III, L.P. and affiliated entities filed a Schedule 13D disclosing beneficial ownership of 9.995% of Korsana Biosciences, Inc. (formerly Cyclerion Therapeutics, Inc.) common stock following the closing of a merger on September 8, 2026. The Reporting Persons acquired their stake through a series of private offerings in Old Korsana between November 2024 and the merger closing, paying an aggregate purchase price of $134,843,200 for securities that converted into approximately 4,552,277 shares of common stock (on an as-converted basis) plus pre-funded warrants. The filing notes that due to beneficial ownership blockers, the Reporting Persons are currently capped at 9.99% ownership and cannot convert Series B Preferred or exercise Pre-Funded Warrants beyond that threshold.

• · The Reporting Persons' ownership is capped at 9.99% due to Beneficial Ownership Blockers in the Series B Preferred and Pre-Funded Warrants, which can be increased to up to 19.99% upon 61 days' notice to the Issuer.
• · Nimish Shah and Andrew Gottesdiener, both partners of Venrock, serve as directors of Korsana Biosciences.
• · The Pre-Funded Warrants have a nominal exercise price of $0.0001 per share, do not expire, and are exercisable on a cash or cashless basis.
• · The Reporting Persons reserve the right to increase or decrease their holdings, including through Rule 10b5-1 trading plans, and may propose extraordinary corporate transactions such as mergers, reorganizations, or asset sales.
• · No transactions in the Issuer's securities were effected by the Reporting Persons during the past 60 days prior to the filing.

15-09-2026

CEO Jason Wilk entered a variable prepaid forward contract on September 11, 2026, receiving $10.9 million upfront from UBS AG against 37,090 shares, while retaining voting rights. He now beneficially owns 1,530,172 shares (11.8%) of Dave Inc., down from prior levels due to share sales under a 10b5-1 plan in September 2025. The filing shows a net reduction in his stake, and shares withheld for tax purposes in September 2026.

• · Wilk sold a total of 100,000 shares under a 10b5-1 plan in September 2025 (15,359 + 2,948 + 81,693). The plan was terminated on September 19, 2025.
• · On September 2, 2026, 7,809 shares were withheld by the issuer at $372.85 per share to satisfy tax withholding upon RSU vesting.
• · The forward contract has a maturity date of August 30, 2029, with settlement price bands: Minimum Price $319.33, Maximum Price $481.48.
• · No other transactions in Class A Common Stock occurred during the past 60 days.

15-09-2026

Leonard M. Tannenbaum, CEO and Chairman of Advanced Flower Capital Inc. (AFCG), filed Amendment No. 9 to his Schedule 13D on September 15, 2026, disclosing an increase in his beneficial ownership of AFCG common stock by approximately 1.2 percentage points to 31.6% of outstanding shares. The increase resulted from open-market purchases of 243,052 shares between August 26 and September 14, 2026, using personal funds, and from the company's share repurchases that reduced the total share count. Tannenbaum now directly holds 6,924,497 shares, with an additional 180,400 shares held by the Tannenbaum Family Foundation (which he disclaims beneficial ownership of except for his pecuniary interest).

• · Tannenbaum disclaims beneficial ownership of 180,400 shares held by the Tannenbaum Family Foundation, except for his pecuniary interest.
• · 226,907 shares held by spouse Robyn Tannenbaum are excluded from beneficial ownership.
• · The company's share repurchase program contributed to the increase in Tannenbaum's ownership percentage by reducing total outstanding shares.
• · Purchase prices ranged from $3.40 to $3.60 per share across the transactions.
• · The filing was made under SEC rule 13D, indicating Tannenbaum holds more than 5% of AFCG common stock.

15-09-2026

Jeffrey Sharpe, a director of Conexeu Sciences Inc., filed an amended Schedule 13D reporting his updated beneficial ownership after exercising 500,000 performance warrants on September 14, 2026. As of that date, he beneficially owns 1,500,000 shares of common stock, representing 5.2% of the 28,706,698 shares outstanding, with sole voting and dispositive power. The warrants were exercised at $0.001 per share for aggregate proceeds of $500, funded from personal funds, following the achievement of a market capitalization milestone of $80 million or greater for 20 consecutive trading days on the Nasdaq.

• · The 500,000 unvested warrants (Milestone 4) will vest upon submission of a 510(k) application to the FDA.
• · Milestone 1 (collagen study) was achieved on July 8, 2025; the corresponding 500,000 warrants were exercised on December 23, 2025.
• · Milestone 2 (Nasdaq listing) was achieved on May 21, 2026; the corresponding 500,000 warrants were exercised on May 22, 2026.
• · Milestone 3 ($80M market cap for 20 consecutive trading days) was achieved on June 18, 2026; the corresponding 500,000 warrants were exercised on September 14, 2026.
• · The exercise price for all performance warrants is $0.001 per share.
• · No other transactions in common stock were effected by the reporting person in the past 60 days.

15-09-2026

Kenneth Rickel filed a Schedule 13G on September 15, 2026, disclosing beneficial ownership of 5,250,000 shares of Hepion Pharmaceuticals, Inc. common stock, representing a 5.7% stake. This includes 2,000,000 shares issuable upon exercise of warrants, but the overall percentage is calculated based on 90,219,317 shares outstanding as of August 10, 2026.

• · The filing was made under Rule 13d-1(c), indicating the securities are not held with the purpose of changing or influencing control.
• · Kenneth Rickel disclaims beneficial ownership of all shares except to the extent of his pecuniary interest.

15-09-2026

Samsara BioCapital, L.P. and affiliated entities filed a Schedule 13G with the SEC, disclosing aggregate beneficial ownership of 7,577,467 shares of PMV Pharmaceuticals, Inc. common stock, representing 9.9% of the company's outstanding shares as of September 2, 2026. The filing notes that a beneficial ownership blocker in certain warrants prevents the group from exercising beyond a 9.99% ownership threshold, effectively limiting their current economic exposure. The filing also reports that Srinivas Akkaraju, the managing member of the general partners, beneficially owns the same 9.9% stake.

• · Total outstanding shares referenced: 53,458,058 as of August 14, 2026, plus 22,055,000 shares issued in a public offering closing on September 2, 2026.
• · Warrants include pre-funded warrants exercisable for up to 3,400,000 shares and common warrants exercisable for up to 7,020,000 shares, each subject to a 9.99% beneficial ownership blocker.
• · The filing explicitly disclaims group status among the reporting persons.
• · No period-over-period comparisons are available in a one-time beneficial ownership filing; all figures represent a point-in-time snapshot.

15-09-2026

Squadra Investments reported a 4.9% beneficial ownership stake in Inter & Co, Inc. as of September 8, 2026, holding 16,056,009 Class A Common Shares. The filing is a Schedule 13G/A amendment disclosing that voting and dispositive power rests with the investment managers and their control person, Mr. Guilherme Mexias Ache. No change in control or activist intent is indicated; the shares were acquired in the ordinary course of business.

• · The Reporting Persons disclaim beneficial ownership of the securities covered by the statement.
• · The filing is an amendment to Schedule 13G and was made under Rule 13d-1(b).
• · Shares held are owned indirectly through investment funds and managed accounts for which Squadra provides discretionary advisory services.

15-09-2026

Randal A. Nardone filed an amended Schedule 13D with the SEC on September 15, 2026, disclosing that as of September 11, 2026, he ceased to be a beneficial owner of more than 5% of New Fortress Energy Inc.'s Class A Common Stock. The filing reflects a 1-for-50 reverse stock split effective September 11, 2026, and a greater than 1% change in his ownership percentage due to the company's restructuring transaction. Nardone reported beneficial ownership of 523,930 Class A Shares, representing 3.2% of the 16,321,555 shares outstanding, down from a prior ownership level above 5%.

• · The filing is Amendment No. 4 to the original Schedule 13D filed on February 4, 2019.
• · Nardone has not engaged in any transactions involving Class A Shares during the past 60 days.
• · The reverse stock split was at a ratio of 1-for-50.
• · The restructuring transaction was described in the Issuer's Definitive Proxy Statement on Schedule 14A filed on May 27, 2026.

15-09-2026

RainForest Partners, LLC disclosed beneficial ownership of 180,258 shares of GT Biopharma, Inc. common stock, representing 9.99% of the outstanding shares as of September 15, 2026. The filing is made under Rule 13d-1(c) and includes a contractually stipulated ownership restriction capping beneficial ownership at 9.99%.

• · The beneficial ownership is subject to a contractual 9.99% ownership restriction; full conversion/exercise of securities would exceed this limit.
• · Filing is under Rule 13d-1(c) and the filer certifies the securities were not acquired to change or influence control.
• · GT Biopharma's common stock has par value of $0.001 per share.

15-09-2026

The Michael & Susan Dell Foundation, along with Michael S. Dell and Susan Lieberman Dell, filed an amended Schedule 13D disclosing beneficial ownership of 27,648,236 Class I shares of Diameter Dynamic Credit Fund, representing 55.4% of the outstanding Class I shares. The amendment was triggered solely by a change in the number of outstanding shares, not by any new transactions, as the reporting persons have not effected any transactions in the past 60 days. The filing reflects a continued majority stake with no recent buying or selling activity.

• · The amendment was filed on September 15, 2026, and is the first amendment to the initial Schedule 13D filed on May 7, 2026.
• · No transactions in the securities were effected by the reporting persons during the past 60 days.
• · The change in ownership percentage was due to a change in the number of outstanding Class I shares of the issuer, not due to any purchases or sales by the reporting persons.

15-09-2026

Pantera Capital entities and Daniel W. Morehead filed a Schedule 13D/A disclosing that on September 11, 2026, Pantera Blockchain Fund LP exercised Cash Pre-Funded Warrants for 1,000,000 Class A Common Shares at $0.001 per share ($1,000 total). As a result, the Pantera group now beneficially owns 5,997,319 shares (9.76%) of Solana Co, up from a prior stake that was already above 5%. The filing shows a large, concentrated position but no plans for a change of control or other major transactions.

• · The warrant exercise price was $0.001 per share, indicating these were deeply in-the-money pre-funded warrants.
• · The filing is an amendment (No. 2) to the original Schedule 13D filed September 25, 2025.
• · No transactions in Common Stock were effected by the Reporting Persons during the past sixty days other than the warrant exercise.
• · The Reporting Persons disclaim beneficial ownership except for pecuniary interest.
• · Pantera Blockchain Fund LP is organized in Delaware; Pantera DAT Opportunities Master Fund SP is organized in the Cayman Islands.

15-09-2026

JATT Ventures II L.P., the sponsor of JATT II Acquisition Corp., filed a Schedule 13D disclosing beneficial ownership of 1,800,000 ordinary shares, representing 23.10% of the issuer's outstanding shares as of June 30, 2026. The sponsor acquired the shares through a private placement purchase agreement dated April 16, 2026, and a founder share purchase agreement dated February 12, 2026, paying $25,000 for 1,725,000 founder shares. The filing indicates no current plans for additional acquisitions, board changes, or other major corporate actions, and the sponsor has agreed to vote in favor of a proposed business combination and not to seek redemption rights.

• · The Sponsor acquired 1,725,000 founder shares for $25,000 (approximately $0.014 per share) on February 12, 2026, of which 225,000 were forfeited subject to the expiration of the underwriters' over-allotment option.
• · The reporting persons have not effected any transactions in the issuer's ordinary shares during the 60 days preceding the filing date.
• · The Sponsor agreed to vote all ordinary shares in favor of a proposed business combination and not to seek redemption rights.
• · The Sponsor disclaims beneficial ownership of securities held by the Sponsor other than to the extent of any pecuniary interest.

15-09-2026

Allen Family Digital, LLC, controlled by Byron Allen, has acquired 45,700,000 shares of BuzzFeed, Inc. Class A Common Stock, representing a 53.5% beneficial ownership stake. The transaction includes registration rights for the purchaser and standard representations and warranties. This significant stake acquisition positions Allen Family Digital as the majority shareholder of BuzzFeed.

• · The filing is an Amendment No. 2 to Schedule 13D, dated September 11, 2026.
• · The share purchase agreement includes provisions for removal of restrictive legends and registration rights on Form S-3.
• · The registration statement must be filed within 60 days of a request by the purchaser and kept effective until shares can be sold under Rule 144 without restrictions.
• · The company bears all expenses related to the registration statement, including legal fees for the purchaser's counsel.
• · The purchaser may be required to suspend use of the registration statement up to two times per 365-day period for up to 90 days each under certain conditions.